| | Roche's schizophrenia drug misses goal in two late-stage trials | ZURICH (Reuters) - An experimental Roche drug designed to treat the "negative symptoms" of schizophrenia failed to meet its main goal in two late-stage studies, dealing a blow to the Swiss drugmaker's research hopes in the risky area of brain science. | | | | China pollution wafting across Pacific to blanket U.S.: study | BEIJING (Reuters) - Pollution from China travels in large quantities across the Pacific Ocean to the United States, a new study has found, making environmental and health problems unexpected side effects of U.S. demand for cheap China-manufactured goods. | | | | Pluristem stem cell trial to treat muscle injury meets main goal | TEL AVIV (Reuters) - Pluristem Therapeutics Inc said results from its early/mid-stage clinical trial indicated its placenta-derived stem cells for the treatment of muscle injury were safe and provided evidence the cells might be effective in treating orthopedic injuries. | | | | | | Saliva reveals asthmatic kids' smoke exposure | NEW YORK (Reuters Health) - Asthmatic children who are exposed to cigarette smoke are more likely to make repeat trips to the hospital for breathing problems. But researchers say asking parents about kids' smoke exposure may not yield the most reliable information. | | | | | More infected in fresh wave of China bird flu - WHO | LONDON (Reuters) - Another 23 people in China have been infected with the H7N9 strain of bird flu in recent days, the World Health Organisation (WHO) said on Monday, adding to at least 24 new cases last week and confirming a fresh surge in the virus. | | | | | | | The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today | | | | | | | A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today | | | | | » MORE NEWSLETTERS | |
No comments:
Post a Comment